Work

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

Year: 2024

Type: article

Study design: Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(24)00310-6

Authors: Peter A Campochiaro, Robert Avery, David M Brown, Jeffrey S Heier, Allen C Ho, Stephen M Huddleston, Glenn J Jaffe, Arshad M Khanani, Stephen Pakola, Dante J Pieramici, Charles C Wykoff, Sherri Van Everen

Institutions: Johns Hopkins University, Johns Hopkins Medicine, California Retina Consultants, Retina Consultants of Texas, Ophthalmic Consultants of Boston, Thomas Jefferson University, University of Tennessee Health Science Center, Duke University, Duke Medical Center, Sierra Eye Associates, Regenxbio (United States)

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: REGENXBIO

OpenAlex ID: W4393238641

FWCI: 45.68

Cites: 18

Cited by: 135

Related to: 10